Conclusion. NHFPV is well tolerated and more effective than NCPAP in treatment of TTN. NHFPV might be a novel and safe tool to manage TTN. pathophysiology involves a lack of appropriate cathecholamine release and/or the inability of fetal lung to switch from fluid secretion to fluid absorption and this is related to insufficiency and or dysfunction of the epithelial Na + channel (3) (4) (5) . Risk factors include maternal asthma, male sex, macrosomia, maternal diabetes, and caesarean delivery (2, 6) . The clinical presentation includes tachypnea and signs of respiratory distress immediately after birth or within two hours. Symptoms can last from a few hours to three days with possible complications such as pneumothorax or pulmonary hypertension (2, 6) . Treatment of neonatal respiratory distress is initially non-invasive ventilation with facial oxygen, nasal continuous positive airway pressure (NCPAP) eventually associated with oxygen therapy and mechanical ventilation in severe cases (6) . Oral furosemide has not been shown to significantly improve status and should not be given (7) . High frequency percussive ventilation (HFPV) is a pressure limited, time-cycled, high-frequency mode of ventilation that delivers subphysiologic tidal volumes at rapid rates and that can be used via an endotracheal tube, a nasal probe or a face mask (8) (9) (10) . In the endotracheal mode, in adults it has been shown to provide the same or improved oxygenation and ventilation at lower peak, mean and end-expiratory pressures when compared with conventional ventilation (11, 12) . In neonates, HFPV has been described in hyaline membrane disease and acute respiratory failure ventilation with improvement in oxygenation, significant decrease in P CO2 and no change in central hemodynamics (13, 14) . In the non endothracheal mode it has the potential to improve secretion clearance and has been 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were the duration and level of oxygen supplementation, and the incidence of pneumothorax, and pulmonary infections. Study entry criteria were infant newborns born by caesarian section ≥ 37 wk gestational age (GA) and of ≥ 2000 g birth weight, transcutaneous oxygen saturation < 90% on room air, simplified Silverman score: (chest movement, expiratory grunt and nares dilation) ≥ 5, neonates managed within 20 minutes of birth. Before randomization infants were filmed and the inclusion criteria were checked by an independent observer. Prior to cesarean section parents were informed of the protocol and when necessary the consent and the randomization were obtained between birth and initiation of respiratory support.
Exclusion criteria included major congenital malformation or pulmonary malformation; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Fig 2B, Fig 2C) , powered by compressed gas that generates the oscillations in the range of 80-650 cycles/min (8, 22 
Ethics
The research protocol for this study was approved by the institutional review board of the University Hospital of Bordeaux (France). The research protocol was registered in ClinicalTrials.gov (NCT00556738). (Fig 3) . The duration of oxygen supplementation was significantly decreased in the NHFPV group (6.3 min ± 3.3) compared with the NCPAP group (19.1 min ± 8.1) (p < 0.001) (Fig 4) . The level of oxygen administrated during the treatment was significantly decreased in the NHFPV group (0.29 min -1 ± 0.16) compared with the NCPAP group (0.46 min -1 ± 0.50) (p < 0.001) (Fig 5) .
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In this prospective, randomized, controlled study, we showed that NHFPV is a well tolerated mode of nasal ventilation for neonates. Moreover we showed a superiority of NHFPV for ventilation care of TTN in comparison to NCPAP. There was a significant decrease of respiratory distress and oxygen therapy duration and a significant decrease of oxygen therapy level in the NHFPV group. NHFPV is a new approach to ventilation assistance of respiratory distress and in our knowledge this is the first prospective randomized controlled study of HFPV in the newborn population.
To date, few studies have been published on the use of HFPV in paediatric patients with pulmonary disease. HFPV has been used in a non endotracheal mode for the treatment of atelectasis and retained secretions in cystic fibrosis or neuromuscular diseases (15) (16) (17) (18) 20) .
Pfenninger et al. described endotracheal use of HFPV in two studies of neonates with hyaline membrane disease and acute respiratory failure. They showed improvement in oxygenation, a significant decrease of PCo 2 and no change in central hemodynamics (13, 14) .
Transient tachypnea of the newborn is a self limited disease which is common in infants and may be prolonged over a 24-72 hour period with few potential complications including hypoxia, respiratory fatigue or air leaks (pneumothorax, pneumomediatinum) (6).
This usually benign respiratory distress was studied as a proof of concept of the usefulness of HFPV in neonates. TTN is the result of a delay in clearance of fetal lung liquid. For effective gas exchange to occur, alveolar spaces must be cleared of excess fluid and the pulmonary blood flow increased to match ventilation with perfusion. Failure of these events can cause the infant to develop respiratory distress (27) (28) (29) . An additional proposed benefit of HFPV is the generation of intrapulmonary mechanical percussive waves, which may aid in the lysis and clearance of airway mucus and secretions (10, (30) (31) (32) (33) (34) . The increase of the fetal lung liquid clearance by HFPV could explain in part the results of our study.
The significant decrease of duration and level of oxygen delivered in the NHFPV group was hardly of clinical importance but this result confirms an effective and well tolerated mode of ventilation. Moreover respiratory distress could induce excess cost (35) and NHFPV could be significant in term of workload and cost reduction for respiratory distress care in this population.
This ventilation mode is a low cost device and is easily used. It was well tolerated by the infants with no complication observed even if the small sample size of our study do not allow a full safety evaluation. No serious adverse effects of HFPV have been reported in previous adult or infant studies (10, 13-17, 34, 36, 37).
Our study has several limitations. Firstly this is not a blinded study, secondly the inclusion criteria and primary endpoint were defined by clinical criteria like Silverman score.
It could have induced bias of interpretation by minimizing the severity of infants included or modify the interpretation of respiratory distress recovery. To correct this bias, the inclusion criteria were reinforced by oxygen saturation as objective element and a delay of 20 minutes after birth to evaluate the infant after the common birth transition period. Moreover the neonate include were filmed before the randomization and the inclusion criteria were checked by an independent observer. At last, the respiratory distress recovery was also defined by a respiratory rate ≤ 60 per minute and a saturation ≥ 95 % without oxygen, wich are not (Fig 2A) . Image ( Fig 2B) and schematic (Fig 2C) Conclusion. NHFPV is well tolerated and more effective than NCPAP in treatment of TTN. NHFPV might be a novel and safe tool to manage TTN. (6) . Oral furosemide has not been shown to significantly improve status and should not be given (7) . High frequency percussive ventilation (HFPV) is a pressure limited, time-cycled, high-frequency mode of ventilation that delivers subphysiologic tidal volumes at rapid rates and that can be used via an endotracheal tube, a nasal probe or a face mask (8) (9) (10) . In the endotracheal mode, in adults it has been shown to provide the same or improved oxygenation and ventilation at lower peak, mean and end-expiratory pressures when compared with conventional ventilation (11, 12) . In neonates, HFPV has been described in hyaline membrane disease and acute respiratory failure ventilation with improvement in oxygenation, significant decrease in P CO2 and no change in central hemodynamics (13, 14) . In the non endothracheal mode it has the potential to improve secretion clearance and has been 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were filmed and the inclusion criteria were checked by an independent observer. Prior to cesarean section parents were informed of the protocol and when necessary the consent and the randomization were obtained between birth and initiation of respiratory support.
Exclusion criteria included major congenital malformation or pulmonary malformation; were evaluated every 5 minutes by an independent observer. Respiratory and cardiac monitoring (oxygen saturation, respiratory rate, heart rate) were continuously recorded and the end points were evaluated secondarily by an independent observer. The fraction of inspired oxygen (FiO 2 ) was adjusted continuously to keep saturations at 90% to 96%. The newborns were monitored during 72 hours following birth in order to record eventual complications (pneumothorax and pulmonary infection).
Study Definitions
We undertook a «simplified Silverman score» defined by the Silverman score without the item regarding chest wall retraction (chest movements, expiratory grunting and nasal flaring ) in order to avoid the inclusion of patients presenting with another diagnosis such as HMD The high frequency percussive ventilator (VDR3, Percussionaire, Bird technologies, Sandpoint, ID) is a pneumatically powered, time cycled, and pressure limited ventilator (Fig   2A) . It is a ventilatory technique that delivers small bursts of high flow respiratory gas into the lung at high rates. Unique to the HFPV is the presence of a sliding venturi system (phasitron, Fig 2B, Fig 2C) , powered by compressed gas that generates the oscillations in the range of 80-650 cycles/min (8, 22) . Airway pressures oscillates between 2 to 35 cmH 2 O and the airway walls vibrate in synchrony with these oscillations. In non endotracheal mode, HFPV can be delivered via a facial mask or a nasal probe (9, 10)( Fig 2B) .
Respiratory Management
CPAP or NHFPV were delivered via a heated humidified nasal probe. In the CPAP group the PEEP was delivered via a conventional time cycled, pressure limited ventilator (Babylog 8000, Drager). NCPAP setting was 5 cm H 2 O and fraction of inspired oxygen (FiO 2 ) adjusted to keep saturations at 90% to 96%. The setting of NHFPV was as follows : pressure of 5 cm H 2 O, high-frequency ventilator at 5Hz as previously described for non-endotracheal respiratory support (9, 26) and fraction of inspired oxygen (FiO 2 ) adjusted to keep saturations at 90% to 96% (Fig 2) . The O 2 saturation probe placement was standardized on preductal location. The HFPV and NCPAP setting were not changed during the procedure. There was no systematic control of the PCO2, but infants who exhibited a deterioration of the respiratory distress under nasal ventilation were monitored by blood gas analyses, x-ray, blood testing, in order to look for a differential diagnosis of TTN (HMD, infection, pneumothorax…). 
Ethics
The research protocol for this study was approved by the institutional review board of the University Hospital of Bordeaux (France). The research protocol was registered in ClinicalTrials.gov (NCT00556738).
RESULTS
Between November 2007 and September 2009, 46 infants were enrolled in the study.
4 infants were excluded after randomization because of secondary diagnosis of HMD and 2 because of diagnosis of neonatal asphyxia associated with TTN (Fig 1) . There were no statistical differences between the 2 groups with regard to any of the baseline maternal and infant characteristics (table 1) . There was no complication (pneumothorax, pulmonary infection, local intolerance) in infants studied. The two modes of ventilation were clinically well tolerated without need for sedation. All infants improved clinically on the given form of support, without necessitating formal mechanical ventilation. The respiratory distress duration was significantly decreased in the NHFPV group (105 min ± 20) compared with the NCPAP (Fig 3) . The duration of oxygen supplementation was significantly decreased in the NHFPV group (6.3 min ± 3.3) compared with the NCPAP group (19.1 min ± 8.1) (p < 0.001) (Fig 4) . The level of oxygen administrated during the treatment was significantly decreased in the NHFPV group (0.29 min -1 ± 0.16) compared with the NCPAP group (0.46 min -1 ± 0.50) (p < 0.001) (Fig 5) .
DISCUSSION
This usually benign respiratory distress was studied as a proof of concept of the usefulness of HFPV in neonates. Our study has several limitations. Firstly this is not a blinded study, secondly the inclusion criteria and primary endpoint were defined by clinical criteria like Silverman score.
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